Drugs / GSK3179106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02798991 | Jun → Nov 2016 | irritable bowel syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02727283 | Nov 2015 → Mar 2016 | irritable bowel syndrome | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3179106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02798991 ↗ |
| Action | Inhibit | “GSK3179106 is a RET kinase inhibitor” PMID 30277655 ↗ Sep 2018 |
| Modality | Small molecule | — CHEMBL3355009 ↗ |
| Route | Oral | “GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration” NCT02727283 ↗ |
| Target | RET | “GSK3179106 is a RET kinase inhibitor” PMID 30277655 ↗ Sep 2018 |